CNTN · Canton Strategic Holdings, Inc.
$2.16
+0.11 (+5.37%)
At close · Jul 21
Market Cap
$150.78M
Shares
69.80M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$35.92M
-194.5%
FY2025
Diluted EPS
-$1.12
+88.1%
FY2025
Operating Cash Flow
-$16.13M
-47.9%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $2.75M | $3.07M | $6.39M | $3.56M | $2.28M | $1.84M | $847.27K | |
| $51.68M | $17.03M | $6.04M | $5.9M | $4.6M | $1.37M | $671.88K | |
| $54.43M | $20.11M | $12.43M | $9.46M | $6.88M | $3.21M | $1.81M | |
| -$54.43M | -$20.11M | -$12.43M | -$9.46M | -$6.88M | -$3.21M | -$1.81M | |
| — | $28.35K | $13.68K | $16.51K | $1.59M | $831.28K | $246.53K | |
| -$36.7M | -$22M | $236.22K | $136.13K | -$1.59M | $1M | -$609.02K | |
| — | -$42.1M | -$12.2M | — | — | — | — | |
| — | -$6.19M | — | $0 | $0 | — | — | |
| -$80.72M | -$35.92M | -$12.2M | -$9.32M | -$8.47M | -$2.21M | -$2.42M | |
| USD/shares | — | -$1.12 | -$9.41 | -$107.02 | -$280.80 | -$131.25 | — |
| USD/shares | — | -$1.12 | -$9.41 | -$107.02 | -$280.80 | — | — |
| shares | — | 32.05M | 1.3M | 87.08K | 30.18K | 16.95K | 16.93K |
| shares | — | 32.05M | 1.3M | 87.08K | 30.18K | 16.95K | 16.93K |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.68×
EV/EBIT
—
Biotechnology median 26.56×
P/E (TTM)
—
Biotechnology median 7.21×
Valuation over time computed as of each quarter's filing date
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 |
|---|---|---|
| Digital Asset Treasury | -$2,765,292 | — |
| Clinical Stage Bio Technology | -$17,340,774 | -$12,433,792 |